Isomorphic Labs has raised an oversubscribed $5 billion Series C, positioning the AI drug discovery company to scale its simulation engine and therapeutic candidate pipeline. The round follows a prior $1.2 billion Series B and significantly expands resources for IsoDDE, the company’s unified drug design and optimization platform. The funding will support further development across multiple therapeutic areas and modalities, including expansion of translational and clinical development infrastructure aimed at advancing candidates toward the clinic. Co-led involvement includes Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and continued backing from Alphabet and other existing investors. For biotech, the round reflects continued capital inflow into AI-first drug design models that can generate experimental-grade candidate refinement. It also intensifies competitive pressure on both emerging AI biopharma startups and established platform vendors to demonstrate faster translation and measurable preclinical progress. The company is also tied to near-term validation partnerships as it scales toward clinical entry.
Get the Daily Brief